Articles from Evolus, Inc.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpassed one million enrolled consumers and completed the two-millionth Jeuveau® redemption in its Evolus Rewards™ patient loyalty program.

Evolus, Inc. (NASDAQEOLS), a performance beauty company focused on building an aesthetic portfolio, has commenced operations in Australia with the launch of Nuceiva® (prabotulinumtoxinA).

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has been awarded Outstanding CFO of a Public Company by the Orange County Business Journal. The award is given to CFOs for outstanding performance as corporate stewards.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in Canaccord Genuity’s 43rd Annual Growth Conference in Boston.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced it has entered into a definitive agreement to be the exclusive U.S. distributor of a line of five unique dermal fillers currently in late-stage development. The addition of a filler line expands the company’s total addressable U.S. market by 70%1 by adding a $1.6 billion U.S. filler market opportunity to the existing $2.3 billion aesthetic neurotoxin market, with both markets expected to nearly double by 20281. As a result of this product expansion, the company has raised its 2028 revenue outlook by $200 million to $700 million.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023, after the U.S. financial markets close.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has commenced the commercial launch of Nuceiva® (botulinum toxin type A) in Germany and Austria, and is now available for direct order and delivery to customers.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced its preliminary, unaudited net revenue and cash position as of and for the fourth quarter and full-year ended December 31, 2021. The preliminary unaudited results described in this press release are estimates only based on the most current information available to management and are subject to change until the audit of the company’s 2021 financial results is completed and the company reports its full financial results for the fourth quarter and full-year 2021, which is planned for early March 2022.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it has entered into a $125 million term loan financing facility with funds managed by Pharmakon Advisors, L.P.